Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPRINT-Lung: Pembrolizumab for the Prevention of Lung Cancer
NCT03634241Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2018
- Primary completion
- Jan 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in non-small cell lung cancer (NSCLC), Pulmonary nodule, sponsored by University of Texas MD Anderson Cancer Center. Started Nov 2018; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)Pulmonary nodule
Beyond the preview
Go deeper on NCT03634241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03634241.